These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 9212772)
1. The controversy surrounding the pathogenesis of the multiple sclerosis lesion. Lucchinetti CF; Rodriguez M Mayo Clin Proc; 1997 Jul; 72(7):665-78. PubMed ID: 9212772 [TBL] [Abstract][Full Text] [Related]
3. [Pathogenesis of multiple sclerosis and other neural autoimmune diseases]. Lassmann H Verh Dtsch Ges Pathol; 1996; 80():109-15. PubMed ID: 9064993 [TBL] [Abstract][Full Text] [Related]
4. Neuronal injury in chronic CNS inflammation. Zindler E; Zipp F Best Pract Res Clin Anaesthesiol; 2010 Dec; 24(4):551-62. PubMed ID: 21619866 [TBL] [Abstract][Full Text] [Related]
5. T-cell responses to myelin antigens in multiple sclerosis; relevance of the predominant autoimmune reactivity to myelin oligodendrocyte glycoprotein. de Rosbo NK; Ben-Nun A J Autoimmun; 1998 Aug; 11(4):287-99. PubMed ID: 9776706 [TBL] [Abstract][Full Text] [Related]
6. The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies. Racke MK Curr Opin Neurol; 2008 Apr; 21 Suppl 1():S9-S18. PubMed ID: 18388801 [TBL] [Abstract][Full Text] [Related]
7. Autoreactive T cells in multiple sclerosis. Zhang J; Weiner HL; Hafler DA Int Rev Immunol; 1992; 9(3):183-201. PubMed ID: 1285060 [No Abstract] [Full Text] [Related]
8. The myelin-associated oligodendrocytic basic protein (MOBP) as a relevant primary target autoantigen in multiple sclerosis. Kaushansky N; Eisenstein M; Zilkha-Falb R; Ben-Nun A Autoimmun Rev; 2010 Feb; 9(4):233-6. PubMed ID: 19683076 [TBL] [Abstract][Full Text] [Related]
9. [Therapeutic immunomodulation in neurology: from hope to reality. Exemplified by multiple sclerosis]. Schluep M; Regli F Praxis (Bern 1994); 1995 Sep; 84(38):1021-4. PubMed ID: 7481299 [TBL] [Abstract][Full Text] [Related]
10. Emerging concepts in autoimmune encephalomyelitis beyond the CD4/T(H)1 paradigm. Batoulis H; Addicks K; Kuerten S Ann Anat; 2010 Aug; 192(4):179-93. PubMed ID: 20692821 [TBL] [Abstract][Full Text] [Related]
11. Experimental autoimmune encephalomyelitis mediated by CD8+ T cells. Ji Q; Goverman J Ann N Y Acad Sci; 2007 Apr; 1103():157-66. PubMed ID: 17376824 [TBL] [Abstract][Full Text] [Related]
12. The pathology of multiple sclerosis and its evolution. Lassmann H Philos Trans R Soc Lond B Biol Sci; 1999 Oct; 354(1390):1635-40. PubMed ID: 10603616 [TBL] [Abstract][Full Text] [Related]
17. Pathogenic immunity in Theiler's virus-induced demyelinating disease: a viral model for multiple sclerosis. Kim BS; Palma JP; Inoue A; Koh CS Arch Immunol Ther Exp (Warsz); 2000; 48(5):373-9. PubMed ID: 11140464 [TBL] [Abstract][Full Text] [Related]
18. The CD8 T cell in multiple sclerosis: suppressor cell or mediator of neuropathology? Johnson AJ; Suidan GL; McDole J; Pirko I Int Rev Neurobiol; 2007; 79():73-97. PubMed ID: 17531838 [TBL] [Abstract][Full Text] [Related]
19. [Multiple sclerosis: from the immune system to inflammatory demyelination and irreversible neurodegeneration]. Sindic CJ Bull Mem Acad R Med Belg; 2002; 157(7-9):391-8; discussion 398-400. PubMed ID: 12647378 [TBL] [Abstract][Full Text] [Related]
20. A new focal EAE model of cortical demyelination: multiple sclerosis-like lesions with rapid resolution of inflammation and extensive remyelination. Merkler D; Ernsting T; Kerschensteiner M; Brück W; Stadelmann C Brain; 2006 Aug; 129(Pt 8):1972-83. PubMed ID: 16714315 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]